Contributions
Abstract: EP1631
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: Dimethyl fumarate (DMF) is a treatment approved for relapsing-remitting multiple sclerosis(RRMS) DMF can be associated with a decrease in leukocyte and lymphocyte counts that might persist after treatment discontinuation.
Objectives: To make a comparison between patients that develop persistent lymphopenia(L-patients) or not develop lymphopenia(NL-patients) with DMF in order to find differential characteristics that might predict this adverse event.
Material and methods: Retrospective observational study in patients with RRMS treated with
DMF since January2014 to May2018 at a tertiary-care hospital. We compare demographic/disease characteristics and previous disease modifying treatments (DMT) in L-patients and NL-patients and analyze lymphoenia characteristics in L-patients.
Results: 13 patients (6,6%) (9women;4men) had persistent (>6months) ⩽600 lymphocites/mm3 (total sample: 195 patients) The average age in L-patients was 48,8y (SD10,72) Mean time to RRMS diagnosis in L-patients was 12,8y (SD5,34) There were no differences between average age or mean time to MS diagnosis between L-patients and NL-patients. The mean disease-modifying treatment (DMT) before DMF was 1,62 in L-patients and 1,28 in NL-patients (ns) The proportion of different previous DMT was similar in both samples. Basal lymphocyte counts were similar in both groups. In L-patients, mean time to first documented lymphopenia was 8,2m (SD5,19) and mean time to DMF discontinuation was 15,5m (SD7,5m) 12/13 of L-patients developed lymphopenia during the first year of treatment. After DMT discontinuation in L-patients, mean time to lymphocyte count normalisation was 3,5m(SD1,2m) 4 patients had lymphocyte counts fluctuations during the wash-out period(30,77%) None of the patients had relapses during the wash-out period.
Conclusions: In our sample there are no differences between age, sex, basal lymphocyte counts or previous DMT among patients that develop or not lymphopenia with DMF. The proportion of patients who developed lymphopenia was lower to figures in clinical trials and the appearance of lymphopenia occurred in almost all patients during the first year of treatment. None of the patients had relapses during the wash-out period.
Disclosure: Rocío López Ruiz received speaking honoraria from Biogen, Novartis, Sanofi Genzyme, Mylan and Merck Serono. Sara Eichau received speaking honoraria from Biogen, Novartis, Sanofi Genzyme and Merck Serono. Miryam Pérez Gámez: nothing to disclose. Juan Luis Ruiz-Peña received speaker honoraria from Biogen-Idec, Sanofi Genzyme, Merck-Serono, Teva and Novartis and Almirall. María Dolores Páramo Camino received speaker honoraria from Sanofi Genzyme. Guillermo Navarro Mascarell had travel/accommodations/meeting expenses funded by Biogen, Almirall, Merck Serono, Novartis, Sanofi Genzyme, and Teva. Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck Serono, Almirall and Teva.
Abstract: EP1631
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: Dimethyl fumarate (DMF) is a treatment approved for relapsing-remitting multiple sclerosis(RRMS) DMF can be associated with a decrease in leukocyte and lymphocyte counts that might persist after treatment discontinuation.
Objectives: To make a comparison between patients that develop persistent lymphopenia(L-patients) or not develop lymphopenia(NL-patients) with DMF in order to find differential characteristics that might predict this adverse event.
Material and methods: Retrospective observational study in patients with RRMS treated with
DMF since January2014 to May2018 at a tertiary-care hospital. We compare demographic/disease characteristics and previous disease modifying treatments (DMT) in L-patients and NL-patients and analyze lymphoenia characteristics in L-patients.
Results: 13 patients (6,6%) (9women;4men) had persistent (>6months) ⩽600 lymphocites/mm3 (total sample: 195 patients) The average age in L-patients was 48,8y (SD10,72) Mean time to RRMS diagnosis in L-patients was 12,8y (SD5,34) There were no differences between average age or mean time to MS diagnosis between L-patients and NL-patients. The mean disease-modifying treatment (DMT) before DMF was 1,62 in L-patients and 1,28 in NL-patients (ns) The proportion of different previous DMT was similar in both samples. Basal lymphocyte counts were similar in both groups. In L-patients, mean time to first documented lymphopenia was 8,2m (SD5,19) and mean time to DMF discontinuation was 15,5m (SD7,5m) 12/13 of L-patients developed lymphopenia during the first year of treatment. After DMT discontinuation in L-patients, mean time to lymphocyte count normalisation was 3,5m(SD1,2m) 4 patients had lymphocyte counts fluctuations during the wash-out period(30,77%) None of the patients had relapses during the wash-out period.
Conclusions: In our sample there are no differences between age, sex, basal lymphocyte counts or previous DMT among patients that develop or not lymphopenia with DMF. The proportion of patients who developed lymphopenia was lower to figures in clinical trials and the appearance of lymphopenia occurred in almost all patients during the first year of treatment. None of the patients had relapses during the wash-out period.
Disclosure: Rocío López Ruiz received speaking honoraria from Biogen, Novartis, Sanofi Genzyme, Mylan and Merck Serono. Sara Eichau received speaking honoraria from Biogen, Novartis, Sanofi Genzyme and Merck Serono. Miryam Pérez Gámez: nothing to disclose. Juan Luis Ruiz-Peña received speaker honoraria from Biogen-Idec, Sanofi Genzyme, Merck-Serono, Teva and Novartis and Almirall. María Dolores Páramo Camino received speaker honoraria from Sanofi Genzyme. Guillermo Navarro Mascarell had travel/accommodations/meeting expenses funded by Biogen, Almirall, Merck Serono, Novartis, Sanofi Genzyme, and Teva. Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck Serono, Almirall and Teva.